Log in
RegisterBCS? [Design Issues]
posted by Helmut 
– Vienna, Austria, 2012-11-28 22:52 (4953 d 05:50 ago) – Posting: # 9625
Views: 12,397
Hi John & A-M-R!
Exactly. Same with EMA’s rules. A-M-R hasn’t stated the regulation he/she is aiming at. Maybe there are still countries with a “positive list” (i.e., drugs where no studies were required at all…). Such lists existed in Germany and Poland, and – until last year for national authorizations only – in The Netherlands. Must have been fun to be an assessor in Holland:
Absolutely. Look at my last sentence above. With nothing published this will be a tough job (I wouldn’t even think about it). Even if one overcomes all these obstacles, the risk assessment will be the show-stopper. A-M-R, to get an idea have a look at FIP’s biowaiver monographs.
Unfortunately many colleagues still think that a biowaiver means only a bunch of nice f2 values and mass balance from the literature. It’s not that easy.
❝ I don't see how A-M-R can bypass BE studies other than going with BCS classifiation (FDA?).
Exactly. Same with EMA’s rules. A-M-R hasn’t stated the regulation he/she is aiming at. Maybe there are still countries with a “positive list” (i.e., drugs where no studies were required at all…). Such lists existed in Germany and Poland, and – until last year for national authorizations only – in The Netherlands. Must have been fun to be an assessor in Holland:
- First dossier: National application. Drug on the positive list. No BE study, no biowaiver requested, only quality data submitted.
Approved.
- Second dossier: Same drug, same test and reference formulations as above. Well, there was no reference above… Concerned member state in a mutual recognition procedure. Two large BE studies, fasting/fed. Fasting study passed, fed study’s Cmax ratio 90% CI 85.00–125.01%.
Rejected.
❝ […] if he goes with BCS it will probably be cheaper and less time consuming in the long run? He also needs to make sure that the reference product is rapidly dissolving (as per FDA guidance).
Absolutely. Look at my last sentence above. With nothing published this will be a tough job (I wouldn’t even think about it). Even if one overcomes all these obstacles, the risk assessment will be the show-stopper. A-M-R, to get an idea have a look at FIP’s biowaiver monographs.
Unfortunately many colleagues still think that a biowaiver means only a bunch of nice f2 values and mass balance from the literature. It’s not that easy.
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна!![[image]](https://static.bebac.at/pics/Blue_and_yellow_ribbon_UA.png)
Helmut Schütz
![[image]](https://static.bebac.at/img/CC by.png)
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
Helmut Schütz
The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Complete thread:
- mebeverine A-M-R 2012-11-22 11:32
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- mebeverine drgunasakaran1 2012-11-22 11:47
- mebeverine bioequivalence A-M-R 2012-11-22 12:12
- mebeverine drgunasakaran1 2012-11-22 11:47
Ing. Helmut Schütz